{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:07:49Z","timestamp":1794629269044,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073399"],"award-info":[{"award-number":["82073399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872443"],"award-info":[{"award-number":["81872443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102934"],"award-info":[{"award-number":["82102934"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203831"],"award-info":[{"award-number":["82203831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipid metabolic reprogramming in colon cancer shows a potential impact on tumor\u00a0immune microenvironment and is associated with response to immunotherapy. Therefore, this study aimed to develop a lipid metabolism-related prognostic risk score (LMrisk) to provide new biomarkers and combination therapy strategies for colon cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Differentially expressed lipid metabolism-related genes (LMGs) including cytochrome P450 (CYP) 19A1 were screened to construct LMrisk in TCGA colon cancer cohort. The LMrisk was then validated in three GEO datasets. The differences of immune cell infiltration and immunotherapy response between LMrisk subgroups were investigated via bioinformatic analysis. These results were comfirmed by in vitro coculture of colon cancer cells with peripheral blood mononuclear cells, human colon cancer tissue microarray analysis, multiplex immunofluorescence staining and mouse xenograft models of colon cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six LMGs including CYP19A1, ALOXE3, FABP4, LRP2, SLCO1A2 and PPARGC1A were selected to establish the LMrisk. The LMrisk was positively correlated with the abundance of macrophages, carcinoma-associated fibroblasts (CAFs), endothelial cells and the levels of biomarkers for immunotherapeutic response including programmed cell death ligand 1 (PD-L1) expression, tumor mutation burden and microsatellite instability, but negatively correlated with CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell infiltration levels. CYP19A1 protein expression was an independent prognostic factor, and positively correlated with PD-L1 expression in human colon cancer tissues. Multiplex immunofluorescence analyses revealed that CYP19A1 protein expression was negatively correlated with CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell infiltration, but positively correlated with the levels of\u00a0tumor-associated macrophages, CAFs and endothelial cells. Importantly, CYP19A1 inhibition downregulated PD-L1, IL-6 and TGF-\u03b2 levels through GPR30-AKT signaling, thereby enhancing CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell-mediated antitumor immune response in vitro co-culture studies. CYP19A1 inhibition by letrozole or siRNA strengthened the anti-tumor immune response of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, induced normalization of tumor blood vessels, and enhanced the efficacy of anti-PD-1 therapy in orthotopic and subcutaneous mouse colon cancer models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      A risk model based on lipid metabolism-related genes may predict prognosis and immunotherapeutic response in colon cancer. CYP19A1-catalyzed estrogen biosynthesis promotes vascular abnormality and inhibits CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell function through the upregulation of PD-L1, IL-6 and TGF-\u03b2\n                      <jats:italic>via<\/jats:italic>\n                      GPR30-AKT signaling. CYP19A1 inhibition combined with PD-1 blockade represents a promising therapeutic strategy for colon cancer immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-023-02647-8","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T01:02:36Z","timestamp":1681347756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer"],"prefix":"10.1186","volume":"42","author":[{"given":"Lilong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongchen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-8629","authenticated-orcid":false,"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"2647_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2647_CR2","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/ijc.33056","volume":"147","author":"MF Tolba","year":"2020","unstructured":"Tolba MF. Revolutionizing the landscape of colorectal cancer treatment: the potential role of immune checkpoint inhibitors. Int J Cancer. 2020;147:2996\u20133006.","journal-title":"Int J Cancer"},{"key":"2647_CR3","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542\u201351.","journal-title":"Lancet Oncol"},{"key":"2647_CR4","doi-asserted-by":"publisher","first-page":"e20201606","DOI":"10.1084\/jem.20201606","volume":"218","author":"X Bian","year":"2021","unstructured":"Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218:e20201606.","journal-title":"J Exp Med"},{"key":"2647_CR5","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1111\/jcmm.14647","volume":"23","author":"F Wu","year":"2019","unstructured":"Wu F, Zhao Z, Chai RC, Liu YQ, Li GZ, Jiang HY, et al. Prognostic power of a lipid metabolism gene panel for diffuse gliomas. J Cell Mol Med. 2019;23:7741\u20138.","journal-title":"J Cell Mol Med"},{"key":"2647_CR6","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.18632\/oncotarget.3130","volume":"6","author":"T Vargas","year":"2015","unstructured":"Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Gonz\u00e1lez-Vallinas M, et al. ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients. Oncotarget. 2015;6:7348\u201363.","journal-title":"Oncotarget"},{"key":"2647_CR7","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.18632\/oncotarget.23592","volume":"9","author":"LP Fern\u00e1ndez","year":"2018","unstructured":"Fern\u00e1ndez LP, Ramos-Ruiz R, Herranz J, Mart\u00edn-Hern\u00e1ndez R, Vargas T, Mendiola M, et al. The transcriptional and mutational landscapes of lipid metabolism-related genes in colon cancer. Oncotarget. 2018;9:5919\u201330.","journal-title":"Oncotarget"},{"key":"2647_CR8","doi-asserted-by":"publisher","first-page":"105644","DOI":"10.1016\/j.phrs.2021.105644","volume":"169","author":"C Jiang","year":"2021","unstructured":"Jiang C, Liu Y, Wen S, Xu C, Gu L. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma. Pharmacol Res. 2021;169:105644.","journal-title":"Pharmacol Res"},{"key":"2647_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12859-019-2734-4","volume":"20","author":"Y Hao","year":"2019","unstructured":"Hao Y, Li D, Xu Y, Ouyang J, Wang Y, Zhang Y, et al. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data. BMC Bioinformatics. 2019;20:195.","journal-title":"BMC Bioinformatics"},{"key":"2647_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semcancer.2012.02.009","volume":"22","author":"E Gottfried","year":"2012","unstructured":"Gottfried E, Kreutz M, Mackensen A. Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol. 2012;22:335\u201341.","journal-title":"Semin Cancer Biol"},{"key":"2647_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370.","journal-title":"Cell"},{"key":"2647_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1124\/jpet.118.254359","volume":"368","author":"H Tang","year":"2019","unstructured":"Tang H, Liu Y, Wang C, Zheng H, Chen Y, Liu W, et al. Inhibition of COX-2 and EGFR by melafolone improves anti-PD-1 therapy through vascular normalization and PD-L1 downregulation in lung cancer. J Pharmacol Exp Ther. 2019;368:401\u201313.","journal-title":"J Pharmacol Exp Ther"},{"key":"2647_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531:651\u20135.","journal-title":"Nature"},{"key":"2647_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/ijms22031258","volume":"22","author":"CY Weng","year":"2021","unstructured":"Weng CY, Kao CX, Chang TS, Huang YH. Immuno-metabolism: the role of cancer niche in immune checkpoint inhibitor resistance. Int J Mol Sci. 2021;22:1258.","journal-title":"Int J Mol Sci"},{"key":"2647_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev.physiol.64.081601.142703","volume":"64","author":"ER Simpson","year":"2002","unstructured":"Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, et al. Aromatase\u2013a brief overview. Annu Rev Physiol. 2002;64:93\u2013127.","journal-title":"Annu Rev Physiol"},{"key":"2647_CR16","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s11010-021-04099-0","volume":"476","author":"D Molehin","year":"2021","unstructured":"Molehin D, Rasha F, Rahman RL, Pruitt K. Regulation of aromatase in cancer. Mol Cell Biochem. 2021;476:2449\u201364.","journal-title":"Mol Cell Biochem"},{"key":"2647_CR17","doi-asserted-by":"publisher","first-page":"7417","DOI":"10.1111\/jcmm.14605","volume":"23","author":"J-C Yang","year":"2019","unstructured":"Yang J-C, Chang N, Wu D-C, Cheng W-C, Chung W-M, Chang W-C, et al. Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer. J Cell Mol Med. 2019;23:7417\u201326.","journal-title":"J Cell Mol Med"},{"key":"2647_CR18","doi-asserted-by":"publisher","first-page":"e213428","DOI":"10.1001\/jamaoncol.2021.3428","volume":"7","author":"Y Fan","year":"2021","unstructured":"Fan Y, Sun T, Shao Z, Zhang Q, Ouyang Q, Tong Z, et al. Effectiveness of adding everolimus to the first-line treatment of advanced breast cancer in premenopausal women who experienced disease progression while receiving selective estrogen receptor modulators: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7:e213428.","journal-title":"JAMA Oncol"},{"key":"2647_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1186\/s12885-021-08612-y","volume":"21","author":"W Wu","year":"2021","unstructured":"Wu W, Chen J, Deng H, Jin L, He Z, Rao N, et al. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. BMC Cancer. 2021;21:862.","journal-title":"BMC Cancer"},{"key":"2647_CR20","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630\u20137.","journal-title":"J Clin Oncol"},{"key":"2647_CR21","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","volume":"16","author":"RH Vonderheide","year":"2010","unstructured":"Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16:3485\u201394.","journal-title":"Clin Cancer Res"},{"key":"2647_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"2647_CR23","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (N Y). 2021;2:100141.","journal-title":"Innovation (N Y)"},{"key":"2647_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"2647_CR25","doi-asserted-by":"publisher","first-page":"i436","DOI":"10.1093\/bioinformatics\/btz363","volume":"35","author":"G Sturm","year":"2019","unstructured":"Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019;35:i436\u201345.","journal-title":"Bioinformatics"},{"key":"2647_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ebiom.2019.02.012","volume":"41","author":"M Wu","year":"2019","unstructured":"Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R, et al. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine. 2019;41:244\u201355.","journal-title":"EBioMedicine"},{"key":"2647_CR27","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1158\/0008-5472.CAN-21-4029","volume":"82","author":"X Chen","year":"2022","unstructured":"Chen X, Liu Y, Wang Y, Wang C, Chen X, Xiong Y, et al. CYP4F2-catalyzed metabolism of arachidonic acid promotes stromal cell-mediated immunosuppression in non-small cell lung cancer. Cancer Res. 2022;82:4016\u201330.","journal-title":"Cancer Res"},{"key":"2647_CR28","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557\u201366.","journal-title":"Cancer Res"},{"key":"2647_CR29","doi-asserted-by":"publisher","first-page":"e001437","DOI":"10.1136\/jitc-2020-001437","volume":"8","author":"X Bao","year":"2020","unstructured":"Bao X, Zhang H, Wu W, Cheng S, Dai X, Zhu X, et al. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer. 2020;8:e001437.","journal-title":"J Immunother Cancer"},{"key":"2647_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136.","journal-title":"Nat Genet"},{"key":"2647_CR31","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1158\/1078-0432.CCR-21-0529","volume":"27","author":"L Marisa","year":"2021","unstructured":"Marisa L, Blum Y, Taieb J, Ayadi M, Pilati C, Le Malicot K, et al. Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer. Clin Cancer Res. 2021;27:4768\u201380.","journal-title":"Clin Cancer Res"},{"key":"2647_CR32","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","volume":"22","author":"E Becht","year":"2016","unstructured":"Becht E, de Reynies A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057\u201366.","journal-title":"Clin Cancer Res"},{"key":"2647_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48:812-830.e14.","journal-title":"Immunity"},{"key":"2647_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2019.09.008","volume":"123","author":"B Soldevilla","year":"2019","unstructured":"Soldevilla B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, Riesco MC, Gil-Calderon B, et al. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. Eur J Cancer. 2019;123:118\u201329.","journal-title":"Eur J Cancer"},{"key":"2647_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22:174\u201389.","journal-title":"Nat Rev Cancer"},{"key":"2647_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.semcancer.2022.02.009","volume":"86","author":"TS Anderson","year":"2022","unstructured":"Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin Cancer Biol. 2022;86:981\u201396.","journal-title":"Semin Cancer Biol"},{"key":"2647_CR37","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1210\/jc.2016-3716","volume":"102","author":"LC Gilligan","year":"2017","unstructured":"Gilligan LC, Rahman HP, Hewitt A-M, Sitch AJ, Gondal A, Arvaniti A, et al. Estrogen activation by steroid sulfatase increases colorectal cancer proliferation via gper. J Clin Endocrinol Metab. 2017;102:4435\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"2647_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejphar.2018.01.040","volume":"824","author":"W Yang","year":"2018","unstructured":"Yang W, Tan W, Zheng J, Zhang B, Li H, Li X. MEHP promotes the proliferation of cervical cancer via GPER mediated activation of Akt. Eur J Pharmacol. 2018;824:11\u20136.","journal-title":"Eur J Pharmacol"},{"key":"2647_CR39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/md17060381","volume":"17","author":"Y Cao","year":"2019","unstructured":"Cao Y, Tan YF, Wong YS, Liew MWJ, Venkatraman S. Recent advances in chitosan-based carriers for gene delivery. Mar Drugs. 2019;17:381.","journal-title":"Mar Drugs"},{"key":"2647_CR40","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.2147\/IJN.S203113","volume":"14","author":"W Zhang","year":"2019","unstructured":"Zhang W, Xu W, Lan Y, He X, Liu K, Liang Y. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer. Int J Nanomedicine. 2019;14:5287\u2013301.","journal-title":"Int J Nanomedicine"},{"key":"2647_CR41","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"X Li","year":"2019","unstructured":"Li X, Wenes M, Romero P, Huang SC-C, Fendt S-M, Ho P-C. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16:425\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"2647_CR42","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.2147\/OTT.S315998","volume":"14","author":"H Zhang","year":"2021","unstructured":"Zhang H, Zhao W, Li X, He Y. Cholesterol metabolism as a potential therapeutic target and a prognostic biomarker for cancer immunotherapy. Onco Targets Ther. 2021;14:3803\u201312.","journal-title":"Onco Targets Ther"},{"key":"2647_CR43","doi-asserted-by":"publisher","first-page":"9389","DOI":"10.2147\/OTT.S251965","volume":"13","author":"GT Ruan","year":"2020","unstructured":"Ruan GT, Gong YZ, Zhu LC, Gao F, Liao XW, Wang XK, et al. The perspective of diagnostic and prognostic values of lipoxygenases mRNA expression in colon adenocarcinoma. Onco Targets Ther. 2020;13:9389\u2013405.","journal-title":"Onco Targets Ther"},{"key":"2647_CR44","doi-asserted-by":"publisher","first-page":"8752862","DOI":"10.1155\/2019\/8752862","volume":"2019","author":"MN Uddin","year":"2019","unstructured":"Uddin MN, Li M, Wang X. Identification of transcriptional signatures of colon tumor stroma by a meta-analysis. J Oncol. 2019;2019:8752862.","journal-title":"J Oncol"},{"key":"2647_CR45","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.18632\/aging.102979","volume":"12","author":"K Lin","year":"2020","unstructured":"Lin K, Huang J, Luo H, Luo C, Zhu X, Bu F, et al. Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer. Aging. 2020;12:5832\u201357.","journal-title":"Aging"},{"key":"2647_CR46","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.","journal-title":"BMJ"},{"key":"2647_CR47","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173-180.","journal-title":"Lancet Oncol"},{"key":"2647_CR48","doi-asserted-by":"publisher","first-page":"691676","DOI":"10.3389\/fcell.2021.691676","volume":"9","author":"Z Ye","year":"2021","unstructured":"Ye Z, Zou S, Niu Z, Xu Z, Hu Y. A novel risk model based on lipid metabolism-associated genes predicts prognosis and indicates immune microenvironment in breast cancer. Front Cell Dev Biol. 2021;9:691676.","journal-title":"Front Cell Dev Biol"},{"key":"2647_CR49","doi-asserted-by":"publisher","first-page":"691143","DOI":"10.3389\/fmolb.2021.691143","volume":"8","author":"X-L Wei","year":"2021","unstructured":"Wei X-L, Luo T-Q, Li J-N, Xue Z-C, Wang Y, Zhang Y, et al. Development and validation of a prognostic classifier based on lipid metabolism-related genes in gastric cancer. Front Mol Biosci. 2021;8:691143.","journal-title":"Front Mol Biosci"},{"key":"2647_CR50","doi-asserted-by":"publisher","first-page":"673827","DOI":"10.3389\/fcell.2021.673827","volume":"9","author":"H Qian","year":"2021","unstructured":"Qian H, Lei T, Hu Y, Lei P. Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis in osteosarcoma. Front Cell Dev Biol. 2021;9:673827.","journal-title":"Front Cell Dev Biol"},{"key":"2647_CR51","doi-asserted-by":"publisher","first-page":"725292","DOI":"10.3389\/fonc.2021.725292","volume":"11","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wang C, Lin S, Yu X. Effect of TTN mutations on immune microenvironment and efficacy of immunotherapy in lung adenocarcinoma patients. Front Oncol. 2021;11:725292.","journal-title":"Front Oncol"},{"key":"2647_CR52","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.21037\/tlcr-20-1118","volume":"10","author":"C Su","year":"2021","unstructured":"Su C, Wang X, Zhou J, Zhao J, Zhou F, Zhao G, et al. Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:1256\u201365.","journal-title":"Transl Lung Cancer Res"},{"key":"2647_CR53","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/med.21765","volume":"41","author":"H Sadeghi Rad","year":"2021","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O\u2019Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41:1474\u201398.","journal-title":"Med Res Rev"},{"key":"2647_CR54","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1158\/1078-0432.CCR-13-0325","volume":"19","author":"A Barzi","year":"2013","unstructured":"Barzi A, Lenz AM, Labonte MJ, Lenz H-J. Molecular pathways: Estrogen pathway in colorectal cancer. Clin Cancer Res. 2013;19:5842\u20138.","journal-title":"Clin Cancer Res"},{"key":"2647_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA. 2013;310:1353\u201368.","journal-title":"JAMA"},{"key":"2647_CR56","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1002\/cncr.29464","volume":"121","author":"S Lavasani","year":"2015","unstructured":"Lavasani S, Chlebowski RT, Prentice RL, Kato I, Wactawski-Wende J, Johnson KC, et al. Estrogen and colorectal cancer incidence and mortality. Cancer. 2015;121:3261\u201371.","journal-title":"Cancer"},{"key":"2647_CR57","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","volume":"21","author":"S Haupt","year":"2021","unstructured":"Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. Nat Rev Cancer. 2021;21:393\u2013407.","journal-title":"Nat Rev Cancer"},{"key":"2647_CR58","doi-asserted-by":"publisher","first-page":"84258","DOI":"10.18632\/oncotarget.20653","volume":"8","author":"V Bustos","year":"2017","unstructured":"Bustos V, Nolan \u00c1M, Nijhuis A, Harvey H, Parker A, Poulsom R, et al. GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions. Oncotarget. 2017;8:84258\u201375.","journal-title":"Oncotarget"},{"key":"2647_CR59","first-page":"3069","volume":"32","author":"R Sato","year":"2012","unstructured":"Sato R, Suzuki T, Katayose Y, Miura K, Shiiba K, Miki Y, et al. Aromatase in colon carcinoma. Anticancer Res. 2012;32:3069\u201375.","journal-title":"Anticancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02647-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T02:03:56Z","timestamp":1681351436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02647-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02647-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal studies were approved by the Animal Research Committee of Wuhan University and maintained in accordance with the guidelines by the Association for Assessment and Accreditation of Laboratory Animal Care International. All human tissue and blood samples were collected with informed consent from patients, and all related procedures were performed with the approval of ethics boards of the Medical School of Wuhan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}